UCP-2 inhibitor enhanced the efficacy of trastuzumab against HER2 positive breast cancer cells.

Jun HuaZhe ZhangLili ZhangYan SunYuan Yuan

Published in: Cancer chemotherapy and pharmacology (2021)

Taken together, our study identified UCP-2 as a novel therapeutic target for HER2 positive breast cancer and UCP-2 inhibitor may have great potential to enhance the response rate and efficacy of trastuzumab therapy.

Keyphrases

positive breast cancer
breast cancer cells
epidermal growth factor receptor
metastatic breast cancer
stem cells
risk assessment
bone marrow
mesenchymal stem cells
tyrosine kinase